Drug Profile
Research programme: ocular therapeutics - Santen Pharmaceutical/Aria Pharmaceuticals
Latest Information Update: 11 May 2021
Price :
$50
*
At a glance
- Originator twoXAR
- Developer Aria Pharmaceuticals; Santen Pharmaceutical
- Class Eye disorder therapies
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Glaucoma